PROTRACTED gastrointestinal symptoms and initial negative antibody tests significantly increase NMOSD misdiagnosis rates among patients. A retrospective cohort analysis of 199 individuals meeting international diagnostic criteria evaluated clinical timelines to uncover why this rare autoimmune central nervous system disorder is frequently mistaken for other conditions. Overall, 35.7% of patients received an initial incorrect diagnosis, with multiple sclerosis accounting for 53 of the 71 misdiagnosed cases.
Clinical Drivers of NMOSD Misdiagnosis
Presenting symptoms strongly influenced diagnostic accuracy across both seropositive and seronegative groups. Patients who experienced protracted nausea, vomiting, or hiccups without accompanying neurological deficits were significantly more likely to receive an inaccurate diagnosis than those accurately identified at presentation (32.4% versus 12.5%). These nonspecific symptoms localize to the area postrema in the dorsal medulla, yet clinicians often attribute them to common gastrointestinal or infectious conditions rather than central nervous system inflammation. Additionally, 32% of all studied patients presented with a skin rash prior to diagnosis, frequently located on the face or extremities.
Diagnostic Delays and Testing Pitfalls
Delayed access to specialized care and neuroimaging compounded the risk of NMOSD misdiagnosis. Misdiagnosed patients waited a median of 4.2 years to see a neuroimmunology specialist, compared with 0.5 years for accurately diagnosed peers, and experienced a median delay of 4.7 years before undergoing their first MRI. Serological testing patterns also revealed critical diagnostic hurdles. Among patients evaluated with live-cell based aquaporin 4-immunoglobulin G (AQP4-IgG) serum assays, 100% of tested individuals in the misdiagnosed group initially received negative results, compared with 19.3% in the accurately diagnosed group. Repeat testing eventually confirmed seropositivity in 61.5% of those initially negative misdiagnosed patients, though the mean interval between negative and positive results spanned 3.9 years.
Clinical Consequences and Management Implications
Diagnostic errors carried substantial healthcare burdens and therapeutic risks. Prior to receiving an accurate diagnosis, misdiagnosed patients attended a median of 10.5 clinic visits or hospitalizations across 5.5 distinct providers, reflecting fragmented care. Because multiple sclerosis disease-modifying therapies can exacerbate neuromyelitis optica spectrum disorder relapses and accelerate permanent disability, clinicians should maintain high suspicion when evaluating unexplained area postrema symptoms and repeat AQP4-IgG testing when clinical concern persists.
Reference
Smith AD et al. Factors associated with the misdiagnosis of neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2023;70:104498.